These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 34248965)

  • 21. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
    Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
    Front Immunol; 2021; 12():782775. PubMed ID: 34790207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
    Badar T; Shah NN
    Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
    Amhaz G; Bazarbachi A; El-Cheikh J
    Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
    Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR T-cell therapy: Full speed ahead.
    Sermer D; Brentjens R
    Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
    Fergusson NJ; Adeel K; Kekre N; Atkins H; Hay KA
    Front Immunol; 2023; 14():1178403. PubMed ID: 37180149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells.
    Bunse M; Pfeilschifter J; Bluhm J; Zschummel M; Joedicke JJ; Wirges A; Stark H; Kretschmer V; Chmielewski M; Uckert W; Abken H; Westermann J; Rehm A; Höpken UE
    Nat Commun; 2021 Jan; 12(1):240. PubMed ID: 33431832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
    JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
    Abramson JS
    Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
    Ravi D; Sarkar S; Purvey S; Passero F; Beheshti A; Chen Y; Mokhtar M; David K; Konry T; Evens AM
    Leukemia; 2020 May; 34(5):1291-1304. PubMed ID: 31772298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.
    Xu X; Huang S; Xiao X; Sun Q; Liang X; Chen S; Zhao Z; Huo Z; Tu S; Li Y
    Front Immunol; 2020; 11():569117. PubMed ID: 33643279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL).
    Chu Y; Lamb M; Cairo MS; Lee DA
    Curr Treat Options Oncol; 2022 Mar; 23(3):381-403. PubMed ID: 35258793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
    Rogosic S; Ghorashian S
    Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
    Munshi PN; Ujjani C
    Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
    Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
    Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
    J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma.
    Banerjee T; Vallurupalli A
    Curr Probl Cancer; 2022 Feb; 46(1):100825. PubMed ID: 35033383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.